Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
about
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem CellsClinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancerCD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected].CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSVOverexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast CancerClinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer.CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysisThe prognostic role of cancer stem cells in breast tumors.Topoisomerase IIβ mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs.CD133 expression associated with poor prognosis in ovarian cancer.HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity.In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasivenessExpression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancerEvaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma.Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer".Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari".Nanomedicine applications in the treatment of breast cancer: current state of the art.Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC.Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancerInadequacy of tissue microarrays for the immunohistochemical detection of cancer stem cells in solid tumors: a viewpoint
P2860
Q28066297-7DB977FB-18F9-4FF6-89E2-AF2E0A90E3D5Q33574875-5D1BE795-075D-4DE0-9EDB-2890AC551BC1Q33798788-40132C5B-7953-4D77-A73B-1DE259F43D3FQ34438511-577450BB-7DDB-4729-8E75-EBC8F35B56D4Q35866920-0BE7CD02-2F21-42C4-9189-71EF119B5AC6Q36030949-945E796E-E947-4D78-984F-CF781816975FQ36092011-1BDA4666-6768-4BEA-B12F-256F1FF14887Q36292530-D6C48AAD-52B9-4400-8179-09E8B0C5057CQ36441530-47EB8560-5C63-40A1-B955-009D7512BDD0Q36962860-4401C495-7D46-4004-8ABC-422F59D7A50DQ37108555-39228B60-0E75-4D74-A6F1-F9E6325F1FE3Q37125974-29EA6FB1-BA93-42DC-8433-948A56D9FB80Q37373712-D9575887-3275-409E-B624-4F9C40E65042Q37376195-38775F5F-2D5C-40CB-915A-912B18593697Q37399964-69C9913E-C5E2-4481-AB8D-78DD6AAC3BFEQ37468314-59B5124F-8A21-4E6F-891E-FD17F4237DEDQ37513954-14D1CEBB-A57A-436D-82D0-D39611737333Q38035206-7EA07584-2C8D-4277-9CA2-1996FAA13674Q38383345-9EEDF29C-15A0-425B-A994-6CD1740C3896Q38949124-FE6BA112-8E8C-4853-BB88-64AD163009F9Q38954672-5A7FB97D-98D6-40B1-9F02-AA22F8BD3FBCQ39399161-6EB99DA8-3661-4DBC-A572-3CE0D6B11434Q39473541-6EE9C59B-4919-475A-AC08-A6E11729F040Q39900695-BE7A54CA-6BC8-4ABE-8669-51B9077B5108Q40695629-FEA27F1C-32E6-4226-910D-44E488357511Q41182171-2F63983B-D203-4206-8BA3-EB5995554D57Q41350562-B4C7B5A2-E2CB-4018-A860-9C3AEBFEA49FQ41483629-BC1AF131-DB16-4675-B359-0BA32340BA7BQ41611344-CF382491-C424-4D00-9BB9-825AA9CCDF2DQ42748057-B4290810-6A1E-4717-A386-164FEF22B7EDQ44473846-629832AC-8AF5-494E-B01B-C833B24BB195Q58572653-CAB8B501-A7BC-478B-8F96-5D586A18528DQ59011730-50FC24E0-B229-407E-BB7C-58351F2C5569
P2860
Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Clinicopathological significan ...... ple-negative breast carcinoma.
@en
Clinicopathological significan ...... ple-negative breast carcinoma.
@nl
type
label
Clinicopathological significan ...... ple-negative breast carcinoma.
@en
Clinicopathological significan ...... ple-negative breast carcinoma.
@nl
prefLabel
Clinicopathological significan ...... ple-negative breast carcinoma.
@en
Clinicopathological significan ...... ple-negative breast carcinoma.
@nl
P2093
P2860
P1433
P1476
Clinicopathological significan ...... ple-negative breast carcinoma.
@en
P2093
P2860
P304
P356
10.1111/J.1349-7006.2011.01894.X
P577
2011-02-28T00:00:00Z